| Literature DB >> 28680592 |
Heidi Högel1,2, Krista Rantanen1,2, Petra Miikkulainen1,2, Tomi Suomi1,3, Petri Kouvonen1, Laura L Elo1, Panu M Jaakkola1,2,4.
Abstract
BACKGROUND: A key feature of clear cell renal cell carcinoma (ccRCC) is the inactivation of the von Hippel-Lindau tumour suppressor protein (pVHL) that leads to the activation of hypoxia-inducible factor (HIF) pathway also in well-oxygenated conditions. Important regulator of HIF-α, prolyl hydroxylase PHD3, is expressed in high amounts in ccRCC. Although several functions and downstream targets for PHD3 in cancer have been suggested, the role of elevated PHD3 expression in ccRCC is not clear.Entities:
Keywords: Discovery proteomics; Hypoxia; Metabolism; PHD3; Ribosomal proteins; Translation; ccRCC
Year: 2017 PMID: 28680592 PMCID: PMC5496173 DOI: 10.1186/s40170-017-0167-y
Source DB: PubMed Journal: Cancer Metab ISSN: 2049-3002
Fig. 1Experimental setup and the effect of PHD3 silencing on 786-O proteome. a siRNA-mediated silencing of PHD3 protein level in 786-O ccRCC cell line using two individual siRNA sequences in normoxic and in hypoxic (1% O2) condition. Quantification of three biological replicates, mean ± SEM, fold change to control (Scr). Asterisk indicates a statistically significant difference (*p < 0.05, **p < 0.01). b siRNA-mediated silencing of PHD3 mRNA expression, quantification of three individual experiments. Mean ± SEM, fold change to Scr (***p < 0.001). c Flow chart of the experimental procedure. 786-O cells were transfected with siPHD3#1 or with a non-targeting control siRNA (Scr) for 24 h followed by a hypoxic (1% O2) or normoxic (21% O2) exposure. Three independent experiments were performed; proteins were extracted, followed by in-gel digestion with trypsin. Purified peptides were ran through mass spectrometer. Protein identification was done with Mascot database search. Protein quantification was carried out with Progenesis QI, followed by testing the differential expression between sample groups using peptide-level expression change averaging (PECA). d Western blot validations of selected proteins in 786-O and RCC4 cell lines with two individual siRNA sequences targeting PHD3, representative analyses are shown
Significantly regulated proteins in response to PHD3 silencing according to PECA analysis under normoxia
| Accession | Protein name | Gene name | Log2 fold change | FDR |
|---|---|---|---|---|
| Upregulated | ||||
| P09493 | Tropomyosin alpha-1 chain | TPM1 C15orf13 TMSA | 1.5144 | 0.0260 |
| P31943 | Heterogeneous nuclear ribonucleoprotein H | HNRNPH1 HNRPH HNRPH1 | 1.3557 | 0.0020 |
| P35527 | Keratin, type I cytoskeletal 9 | KRT9 | 1.0655 | 0.0124 |
| Q15436 | Protein transport protein Sec23A | SEC23A | 0.9224 | 0.0092 |
| P09429 | High mobility group protein B1 | HMGB1 HMG1 | 0.8762 | 0.0000 |
| P51148 | Ras-related protein Rab-5C | RAB5C RABL | 0.7977 | 0.0016 |
| O43852 | Calumenin | CALU | 0.6639 | 0.0007 |
| P38646 | Stress-70 protein, mitochondrial | HSPA9 GRP75 HSPA9B mt-HSP70 | 0.6142 | 0.0000 |
| O75874 | Isocitrate dehydrogenase | IDH1 PICD | 0.5916 | 0.0116 |
| O43707 | Alpha-actinin-4 | ACTN4 | 0.4702 | 0.0008 |
| Q06210 | Glutamine—fructose-6-phosphate aminotransferase | GFPT1 GFAT GFPT | 0.4654 | 0.0449 |
| P07195 |
| LDHB | 0.4116 | 0.0020 |
| P55072 | Transitional endoplasmic reticulum ATPase | VCP | 0.3889 | 0.0002 |
| P11413 | Glucose-6-phosphate 1-dehydrogenase | G6PD | 0.3781 | 0.0116 |
| Downregulated | ||||
| P31939 | Bifunctional purine biosynthesis protein PURH | ATIC PURH OK/SW-cl.86 | −1.6058 | 0.0116 |
| Q92597 | Protein NDRG1 | NDRG1 CAP43 DRG1 RTP | −1.3053 | 0.0000 |
| O15460 | Prolyl 4-hydroxylase subunit alpha-2 | P4HA2 UNQ290/PRO330 | −1.1904 | 0.0000 |
| O43776 | Asparagine—tRNA ligase, cytoplasmic | NARS | −0.9285 | 0.0000 |
| Q6PIU2 | Neutral cholesterol ester hydrolase 1 | NCEH1 AADACL1 KIAA1363 | −0.8525 | 0.0000 |
| Q04637 | Eukaryotic translation initiation factor 4 gamma 1 | EIF4G1 EIF4F EIF4G EIF4GI | −0.8275 | 0.0275 |
| P06733 | Alpha-enolase | ENO1 ENO1L1 MBPB1 MPB1 | −0.7775 | 0.0000 |
| P11166 | Glucose transporter 1 | GLUT1 SLC2A1 | −0.7694 | 0.0006 |
| P54578 | Ubiquitin carboxyl-terminal hydrolase 14 | USP14 TGT | −0.7558 | 0.0114 |
| P68363 | Tubulin alpha-1B chain | TUBA1B | −0.7398 | 0.0016 |
| P21980 | Protein-glutamine gamma-glutamyltransferase 2 | TGM2 | −0.5013 | 0.0003 |
| O00469 | Procollagen-lysine,2-oxoglutarate 5-dioxygenase 2 | PLOD2 | −0.4866 | 0.0003 |
| P35637 | RNA-binding protein FUS | FUS TLS | −0.3575 | 0.0449 |
| Q01082 | Spectrin beta chain, non-erythrocytic 1 | SPTBN1 SPTB2 | −0.2911 | 0.0260 |
Significantly regulated proteins in response to PHD3 silencing according to PECA analysis under hypoxia
| Accession | Protein name | Gene name | Log2 fold change | FDR |
|---|---|---|---|---|
| Upregulated | ||||
| Q9NUQ6 | SPATS2-like protein | SPATS2L DNAPTP6 SP1224 | 5.3018 | 0.0001 |
| P09382 | Galectin-1 | LGALS1 | 3.4357 | 0.0003 |
| P14314 | Glucosidase 2 subunit beta | PRKCSH G19P1 | 3.2139 | 0.0003 |
| P61769 | Beta-2-microglobulin | B2M CDABP0092 HDCMA22P | 2.7460 | 0.0015 |
| Q15436 | Protein transport protein Sec23A | SEC23A | 2.2050 | 0.0004 |
| P27487 | Dipeptidyl peptidase 4 | DPP4 ADCP2 CD26 | 1.8694 | 0.0036 |
| Q9UL46 | Proteasome activator complex subunit 2 | PSME2 | 1.7724 | 0.0272 |
| P25786 | Proteasome subunit alpha type-1 | PSMA1 HC2 NU PROS30 PSC2 | 1.6456 | 0.0026 |
| Q14103 | Heterogeneous nuclear ribonucleoprotein D0 | HNRNPD AUF1 HNRPD | 1.6446 | 0.0004 |
| P31949 | Protein S100-A11 | S100A11 MLN70 S100C | 1.6168 | 0.0023 |
| P27816 | Microtubule-associated protein 4 | MAP4 | 1.5844 | 0.0000 |
| P16949 | Stathmin | STMN1 C1orf215 LAP18 OP18 | 1.5535 | 0.0410 |
| P02751 | Fibronectin | FN1 FN | 1.4429 | 0.0000 |
| P62280 | 40S ribosomal protein S11 | RPS11 | 1.3960 | 0.0174 |
| Q05682 | Caldesmon | CALD1 CAD CDM | 1.2817 | 0.0125 |
| Q08257 | Quinone oxidoreductase | CRYZ | 1.1956 | 0.0005 |
| P37837 | Transaldolase | TALDO1 TAL TALDO TALDOR | 1.1582 | 0.0015 |
| P62258 | 14-3-3 protein epsilon | YWHAE | 1.1466 | 0.0028 |
| P38159 | RNA-binding motif protein, X chromosome | RBMX HNRPG RBMXP1 | 1.1085 | 0.0056 |
| P42224 | Signal transducer and activator of transcription 1-alpha/beta | STAT1 | 1.1037 | 0.0046 |
| P14866 | Heterogeneous nuclear ribonucleoprotein L | HNRNPL HNRPL P/OKcl.14 | 1.0821 | 0.0046 |
| P40926 | Malate dehydrogenase, mitochondrial | MDH2 | 1.0281 | 0.0050 |
| P61254 | 60S ribosomal protein L26 | RPL26 | 1.0050 | 0.0203 |
| P18206 | Vinculin | VCL | 0.9917 | 0.0000 |
| P69905 | Haemoglobin subunit alpha | HBA1; HBA2 | 0.9644 | 0.0410 |
| P39023 | 60S ribosomal protein L3 | RPL3 OK/SW-cl.32 | 0.9556 | 0.0203 |
| Q09666 | Neuroblast differentiation-associated protein AHNAK | AHNAK PM227 | 0.7447 | 0.0003 |
| Downregulated | ||||
| Q9Y678 | Coatomer subunit gamma-1 | COPG1 COPG | −8.0564 | 0.0013 |
| Q9Y3D6 | Mitochondrial fission 1 protein | FIS1 TTC11 CGI-135 | −7.7833 | 0.0205 |
| P43686 | 26S protease regulatory subunit 6B | PSMC4 MIP224 TBP7 | −6.7742 | 0.0040 |
| P40429 | 60S ribosomal protein L13a | RPL13A | −6.4755 | 0.0203 |
| P32970 | CD70 antigen (CD27 ligand) | CD70 CD27L CD27LG TNFSF7 | −6.1143 | 0.0023 |
| Q9Y6M1 | Insulin-like growth factor 2 mRNA-binding protein 2 | IGF2BP2 IMP2 VICKZ2 | −5.1670 | 0.0104 |
| Q02878 | 60S ribosomal protein L6 | RPL6 TXREB1 | −4.4586 | 0.0133 |
| P28066 | Proteasome subunit alpha type-5 | PSMA5 | −4.1528 | 0.0032 |
| P84098 | 60S ribosomal protein L19 | RPL19 | −3.7419 | 0.0000 |
| P26373 | 60S ribosomal protein L13 | RPL13 BBC1 OK/SW-cl.46 | −3.2209 | 0.0029 |
| Q6PIU2 | Neutral cholesterol ester hydrolase 1 | NCEH1 AADACL1 KIAA1363 | −2.9792 | 0.0000 |
| P50914 | 60S ribosomal protein L14 | RPL14 | −2.5631 | 0.0480 |
| Q14566 | DNA replication licencing factor MCM6 | MCM6 | −2.4344 | 0.0203 |
| Q13765 | Nascent polypeptide-associated complex subunit alpha | NACA HSD48 | −2.4075 | 0.0029 |
| P55072 | Transitional endoplasmic reticulum ATPase | VCP | −2.3791 | 0.0375 |
| Q96C19 | EF-hand domain-containing protein D2 | EFHD2 SWS1 | −2.3705 | 0.0061 |
| O76021 | Ribosomal L1 domain-containing protein 1 | RSL1D1 CATX11 CSIG PBK1 L12 | −2.2907 | 0.0339 |
| P21980 | Protein-glutamine gamma-glutamyltransferase 2 | TGM2 | −2.0064 | 0.0001 |
| P18669 | Phosphoglycerate mutase 1 | PGAM1 PGAMA CDABP0006 | −1.9852 | 0.0000 |
| Q96KP4 | Cytosolic non-specific dipeptidase | CNDP2 CN2 CPGL PEPA | −1.9098 | 0.0003 |
| P07437 | Tubulin beta chain | TUBB TUBB5 OK/SW-cl.56 | −1.7965 | 0.0000 |
| P04792 | Heat shock protein beta-1 | HSPB1 HSP27 HSP28 | −1.7811 | 0.0000 |
| O15460 | Prolyl 4-hydroxylase subunit alpha-2 | P4HA2 UNQ290/PRO330 | −1.7067 | 0.0000 |
| Q9Y265 | RuvB-like 1 | RUVBL1 INO80H NMP238 TIP49 TIP49A | −1.6956 | 0.0410 |
| P68363 | Tubulin alpha-1B chain | TUBA1B | −1.4303 | 0.0000 |
| P11166 | Glucose transporter 1 | GLUT1 SLC2A1 | −1.3864 | 0.0004 |
| P36578 | 60S ribosomal protein L4 | RPL4 RPL1 | −1.3288 | 0.0054 |
| P60174 | Triosephosphate isomerase | TPI1 TPI | −1.2345 | 0.0104 |
| P05388 | 60S acidic ribosomal protein P0 | RPLP0 | −1.2313 | 0.0423 |
| P06733 | Alpha-enolase | ENO1 ENO1L1 MBPB1 MPB1 | −1.2069 | 0.0000 |
| P05556 | Integrin beta-1 | ITGB1 FNRB MDF2 MSK12 | −1.1859 | 0.0306 |
| Q01813 | 6-phosphofructokinase, platelet type | PFKP PFKF | −1.0405 | 0.0016 |
| P63104 | 14-3-3 protein zeta/delta | YWHAZ | −0.9364 | 0.0000 |
| P46940 | Ras GTPase-activating-like protein IQGAP1 | IQGAP1 KIAA0051 | −0.9120 | 0.0002 |
| P07355 | Annexin A2 | ANXA2 ANX2 ANX2L4 CAL1H LPC2D | −0.8935 | 0.0000 |
| P00338 |
| LDHA PIG19 | −0.7049 | 0.0004 |
Fig. 2Gene ontology (GO) analysis of genes corresponding to the upregulated and downregulated proteins in response to PHD3 silencing. a Illustration based on the analysis performed with DAVID 6.7 from significantly changed proteins according to PECA analysis for upregulated and downregulated proteins under PHD3 knockdown. Enrichment score was used to rank the annotation groups. b Illustration based on the DAVID results from significantly changed proteins according to PECA analysis for normoxic and hypoxic protein groups separately. Enrichment score was used to rank the annotation groups
Fig. 3PHD3 regulates glucose metabolism of ccRCC cells. a PECA analysis results with log2 fold change and FDR. H hypoxic, N normoxic. Upregulated proteins marked by red and downregulated by blue. b Illustration of the glycolytic pathway. Red ovals represent upregulated and blue ovals downregulated proteins in response to PHD3 knockdown in 786-O cells according to PECA analysis. Clear ovals represent glycolytic enzymes not affected by PHD3 depletion based on LC-MS/MS analysis. c Extracellular lactate concentration normalized to cell count of 786-O and RCC4 cells in normoxia and hypoxia shows a decrease with PHD3 silencing. Quantification of three (786-O) or two (RCC4) biological replicates, mean ± SEM (*p < 0.05, n.s. not significant). d pH measured from 786-O cell culture medium in normoxia and hypoxia shows lower level of extracellular acidification with PHD3 depletion. Hydronium ion concentration was normalized to cell count and converted to pH. Quantification of three biological replicates, mean ± SEM (**p < 0.01, n.s. not significant). e Oxygen consumption rate (OCR) studied with Seahorse XFp Analyser shows an increase in basal OCR and in maximal OCR with PHD3 depletion. Data presented as mean ± SEM, n = 3 (**p < 0.01). f Basal glycolysis function measured with Seahorse XFp Analyser shows a decrease with PHD3 depletion. Mean ± SEM, n = 3. Key: GLUT1 solute carrier family 2, facilitated glucose transporter member 1, HK1 hexokinase 1, G6PD glucose 6-phosphate 1-dehydrogenase, NADPH nicotinamide adenine dinucleotide phosphate, TALDO1 transaldolase, GPI glucose-6-phosphate isomerase, PFKP 6-phosphofructokinase, GFPT glutamine-fructose-6-phosphate aminotransferase, F6P fructose 6-phosphate, F1,6BP fructose 1,6-bisphosphate, ALDO fructose-bisphosphate aldolase, TPI1 triosephosphate isomerase, G3P glyceraldehyde 3-phosphate, GAPDH glyceraldehyde phosphate dehydrogenase, PGK phosphoglycerate kinase, PGAM1 phosphoglyserate mutase 1, 3PG 3-phosphoglycerate, 2PG 2-phosphoglycerate, ENO1 Alpha-enolase, PEP phosphoenolpyruvate, PKM pyruvate kinase isoenzyme M, LDHA l-Lactate dehydrogenase A chain, LDHB l-Lactate dehydrogenase B chain, MDH2 malate dehydrogenase, NADH nicotinamide adenine dinucleotide, IDH1 isocitrate dehydrogenase, αKG alpha-ketoglutarate, NOX normoxia, HOX hypoxia
Fig. 4Functional groups of translation and mRNA processing are regulated in response to PHD3 silencing. a PECA analysis results of LC-MS/MS data with log2 fold change and FDR. H hypoxic, N normoxic. Upregulated proteins marked by red and downregulated by blue. b String analysis showing known interactions between the deregulated proteins by PHD3 knockdown from the group of translation and mRNA processing
Fig. 5PHD3 depletion leads to impaired ccRCC cell growth and decreases the phosphorylation of p70 S6K and S6 ribosomal proteins. a Western blot analysis of 786-O cells with two siRNA sequences targeting PHD3 under normoxia and hypoxia shows decrease in phosphorylation of p70 S6K and S6 ribosomal protein. Right-hand graphs show phosphorylated (S235/236 and S240/244) pS6 ribosomal protein normalized to total S6 protein. Quantification of two biological replicates, mean ± SEM, fold change to Scr (*p < 0.05, n.s. not significant). b Western blot analysis of RCC4 cells with PHD3 depletion under normoxia and hypoxia decreases the phosphorylation of p70 S6K and S6 ribosomal protein. Quantification of two biological replicates, mean ± SEM, fold change to Scr (*p < 0.05, n.s. not significant). c 786-O and RCC4 3D colony forming in Matrigel®. Quantification of three (786-O) or two (RCC4) biological replicates with triplicate wells for each siRNA treatment, mean ± SEM, fold change to Scr (**p < 0.01, ***p < 0.001). Representative images in the panel acquired by using ×4 objective, scale bar 100 μm